Thera-SAbDab

OCRELIZUMAB

>   Structural Summary
TherapeuticOcrelizumab
TargetMS4A1
Heavy ChainEVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSNSYWYFDVWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKPLIYAPSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSFNPPTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv Structure4k7p [Fvs: YX]
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Ocrelizumab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 97.36%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 101 102 103 104 105 106 107 108 109 110 111 112 113
ocrelizumab E V Q L V E S G G G L V Q P G G S L R L S C A A S G Y T F T S Y N M H W V R Q A P G K G L E W V G A I Y P G N G D T S Y N Q K F K G R F T I S V D K S K N T L Y L Q M N S L R A E D T A V Y Y C A R V V Y Y S N S Y W Y F D V W G Q G T L V T V S S
4k7p E V Q L V E S G G G L V Q P G G S L R L S C A A S G Y T F T S Y N M H W V R Q A P G K G L E W V G A I Y P G N G A T S Y N Q K F K G R F T I S V D K S K N T L Y L Q M N S L R A E D T A V Y Y C A R V V Y Y S A S Y W Y F D V W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
ocrelizumab D I Q M T Q S P S S L S A S V G D R V T I T C R A S S S V S - Y M H W Y Q Q K P G K A P K P L I Y A P S N L A S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q W S F N P P T F G Q G T K V E I K
4k7p D I Q M T Q S P S S L S A S V G D R V T I T C R A S S S V - S Y L H W Y Q Q K P G K A P K P L I Y A P S N L A S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q W A F N P P T F G Q G T K V E I K
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)NFD
Recorded Developmental Technologyna
INN Year Proposed2005
INN Year Recommended2006
Companies InvolvedBiogen, Biogen Idec, Chugai Pharmaceutical, Genentech, Roche
Conditions ApprovedMultiple sclerosis
Conditions Activena
Conditions DiscontinuedEye disorders, Haematological malignancies, Lupus nephritis, Rheumatoid arthritis, Systemic lupus erythematosus
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]